Diane Ackroyd, NP
Nurse Practitioner · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 37 years
- Graduated 1989
Offices
1 location · Mindful Health Solutions A Professional Medical Corporation · 55 clinicians in this group
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Diane Ackroyd’s office at (415) 964-5137 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Drugs they prescribed that Part D paid
$10,649
Pharmacies billed $10,649 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 217) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
206 generic and 11 brand-name prescriptions · $10,649 in drug cost · 15 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Olanzapine | 22 | $290 | $13 |
| Gabapentin | 24 | $263 | $11 |
| Bupropion Xl | 12 | $232 | $19 |
| Quetiapine | 24 | $174 | $7 |
| Propranolol | 11 | $170 | $15 |
See all 7 drugs
| Olanzapine | 22 | $290 | $13 |
| Gabapentin | 24 | $263 | $11 |
| Bupropion Xl | 12 | $232 | $19 |
| Quetiapine | 24 | $174 | $7 |
| Propranolol | 11 | $170 | $15 |
| Clonazepam | 22 | $59 | $3 |
| Fluoxetine | 17 | $36 | $2 |
Year by year
| 2024 | 217 | 16 | 0% (0) | 5% | $10,649 |
| 2021 | 20 | None | 0% (0) | 0% | $1,921 |
| 2020 | 112 | 22 | 0% (0) | None | $3,242 |
| 2019 | 119 | 24 | 0% (0) | None | $9,285 |
| 2018 | 64 | 13 | 0% (0) | None | $1,391 |
| 2017 | 33 | None | 0% (0) | 39% | $2,027 |
| 2016 | 25 | None | 0% (0) | None | $1,944 |
| 2015 | 11 | None | 0% (0) | None | $127 |
| 2014 | 79 | None | 0% (0) | 35% | $12,249 |
| 2013 | 125 | 14 | 0% (0) | 22% | $13,293 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2019: 1 drug
| Benztropine Mesylate | 13 | $52 | $4 |
2014: 1 drug
| Sertraline | 18 | $222 | $12 |
2013: 5 drugs
| Abilify | 12 | $11,444 | $954 |
| Bupropion Hcl Sr | 21 | $559 | $27 |
| Sertraline | 24 | $253 | $11 |
| Lamotrigine | 11 | $184 | $17 |
| Lorazepam | 11 | $102 | $9 |
Money from drug and device companies
$779 in 2025
| 2025 | 11 | 34 | None | $779 |
| 2024 | 6 | 11 | None | $319 |
| 2023 | 2 | 2 | None | $149 |
| 2021 | 3 | 4 | None | $488 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Vraylar | $183 | 10 payments
|
| Janssen Pharmaceuticals | Spravato | $112 | 4 payments
|
| Vanda Pharmaceuticals | Hetlioz | $105 | 3 payments
|
| Supernus Pharmaceuticals | None | $89 | 4 payments
|
| Alkermes | Aristada | $85 | 4 payments
|
| Otsuka America Pharmaceutical | Rexulti | $68 | 3 payments
|
See all 34 published payments
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-12-18 | Caplyta | $20 |
| Abbvie | Meals · 2025-12-01 | Vraylar | $19 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-11-17 | Caplyta | $21 |
| Abbvie | Meals · 2025-11-14 | Vraylar | $19 |
| Supernus Pharmaceuticals | Meals · 2025-11-10 | None | $21 |
| Alkermes | Meals · 2025-11-03 | Aristada | $23 |
| Janssen Pharmaceuticals | Meals · 2025-10-27 | Spravato | $18 |
| Abbvie | Meals · 2025-10-20 | Vraylar | $20 |
| Supernus Pharmaceuticals | Meals · 2025-10-13 | None | $23 |
| Janssen Scientific Affairs | Meals · 2025-10-06 | Spravato | $34 |
| Abbvie | Meals · 2025-09-19 | Vraylar | $21 |
| Otsuka America Pharmaceutical | Meals · 2025-09-11 | Rexulti | $27 |
| Alkermes | Meals · 2025-09-08 | Lybalvi | $21 |
| Abbvie | Meals · 2025-09-04 | Vraylar | $17 |
| Janssen Pharmaceuticals | Meals · 2025-08-18 | Spravato | $21 |
| Otsuka America Pharmaceutical | Meals · 2025-08-14 | Rexulti | $19 |
| Abbvie | Meals · 2025-07-25 | Vraylar | $18 |
| Abbvie | Meals · 2025-06-17 | Vraylar | $5 |
| Lundbeck | Meals · 2025-05-17 | Rexulti | $23 |
| Abbvie | Meals · 2025-05-08 | Vraylar | $26 |
| Vanda Pharmaceuticals | Meals · 2025-05-06 | Hetlioz | $33 |
| Bausch Health US | Meals · 2025-05-05 | Aplenzin | $23 |
| Abbvie | Meals · 2025-04-24 | Vraylar | $20 |
| Vanda Pharmaceuticals | Meals · 2025-04-22 | Hetlioz | $39 |
| Alkermes | Meals · 2025-04-15 | Aristada | $14 |
| Alkermes | Meals · 2025-03-24 | Aristada | $28 |
| Supernus Pharmaceuticals | Meals · 2025-03-06 | None | $23 |
| Abbvie | Meals · 2025-03-01 | Vraylar | $17 |
| Janssen Pharmaceuticals | Meals · 2025-02-28 | Spravato | $30 |
| Janssen Pharmaceuticals | Meals · 2025-02-25 | Spravato | $43 |
| Vanda Pharmaceuticals | Meals · 2025-02-20 | Hetlioz | $33 |
| Otsuka America Pharmaceutical | Meals · 2025-01-24 | Rexulti | $21 |
| Supernus Pharmaceuticals | Meals · 2025-01-10 | None | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-07 | Trintellix | $15 |
See earlier years (2024, 2023, 2021)
2024: $319
| Janssen Pharmaceuticals | Spravato | $88 | 2 payments
|
| Abbvie | Vraylar | $86 | 2 payments
|
| Otsuka America Pharmaceutical | Rexulti | $60 | 3 payments
|
| Corium | Azstarys | $46 | 2 payments
|
| Lundbeck | Rexulti | $25 | 1 payment
|
| Axsome Therapeutics | Auvelity | $15 | 1 payment
|
2023: $149
| Janssen Pharmaceuticals | Spravato | $125 | 1 payment
|
| OWP Pharmaceuticals | Subvenite | $24 | 1 payment
|
2021: $488
| AbbVie | Vraylar | $245 | 2 payments
|
| Iti | Caplyta | $122 | 1 payment
|
| Alkermes | Aristada | $120 | 1 payment
|
Professional record
- NPI
- 1083655815
- Licence
- CA 95016167, NY F400-600-1
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- NY 02205310
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X)
- Mailing address
- 4255 Campus Dr Ste A245, Irvine, CA, 92612
- NPI first listed
- 2006-06-10
- NPI last updated
- 2021-07-30
- NPI record certified
- 2021-07-30
This is when the NPI record was last certified, not a medical board exam.